Simplify Logo

Full-Time

Principal or Director

Computational Discovery Science

Posted on 5/16/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Data & Analytics
Hardware
AI & Machine Learning
Financial Services
Biotechnology
Healthcare

Senior, Expert

Boston, MA, USA

Category
Computational Biology
Biology & Biotech
Required Skills
Python
Data Science
R
Data Analysis
Requirements
  • PhD with 6+ years of work experience
  • Quantitative and computational skills (e.g. Computational Biology, Biostatistics/Statistical Genetics, Bioinformatics, Biomedical Informatics, Biometrics, or Data Science for Health)
  • Biological or medical knowledge (e.g. Human Disease, Oncology, Genetics/Genomics, Molecular Biology, or Immunology)
  • Multidisciplinary project team leadership experience
  • Proficient in R or Python packages for computational biology
  • Ability to deliver actionable insights from NGS, clinical, and/or real-world data sets
  • Competency in statistical and mathematical techniques for biological data analysis
  • Experience with early-stage drug development, including target discovery and biomarker identification
  • Comfort in a client-facing role
Responsibilities
  • Utilize novel analytical methods applied to multi-modal data to identify targets in patient sub-populations
  • Use data from CRISPR and cell perturbation experiments in patient-derived organoids to identify and validate novel targets
  • Develop and implement scientific strategies and experimental work plans
  • Mentor and project manage a team of junior scientists or technicians
  • Communicate scientific and technical plans and outcomes to stakeholders
  • Work closely with cross-functional teams
  • Foster a collaborative and inclusive work environment

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

Series G

Total Funding

$1.3B

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

5%

1 year growth

12%

2 year growth

36%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.
INACTIVE